Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 31515
Formulation and in vitro Evaluation of Sustained Release Matrix Tablets of Levetiracetam for Better Epileptic Treatment

Authors: Nagasamy Venkatesh Dhandapani


The objective of the present study was to develop sustained release oral matrix tablets of anti epileptic drug levetiracetam. The sustained release matrix tablets of levetiracetam were prepared using hydrophilic matrix hydroxypropyl methylcellulose (HPMC) as a release retarding polymer by wet granulation method. Prior to compression, FTIR studies were performed to understand the compatibility between the drug and excipients. The study revealed that there was no chemical interaction between drug and excipients used in the study. The tablets were characterized by physical and chemical parameters and results were found in acceptable limits. In vitro release study was carried out for the tablets using 0.1 N HCl for 2 hours and in phosphate buffer pH 7.4 for remaining time up to 12 hours. The effect of polymer concentration was studied. Different dissolution models were applied to drug release data in order to evaluate release mechanisms and kinetics. The drug release data fit well to zero order kinetics. Drug release mechanism was found as a complex mixture of diffusion, swelling and erosion.

Keywords: Levetiracetam, sustained-release, hydrophilic matrix tablet, HPMC grade K 100 MCR, wet granulation, zero order release kinetics.

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1035


[1] Carol M Ulloa et al., Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatric Disease and Treatment, 2009: 467–476.
[2] Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-ontherapyin patients with refractory partial seizures. Epilepsia; 2000; 41: 1179–1186.
[3] Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia, 2001; 42(4): 24–27.
[4] Aulton ME, Wells TI, Pharmaceutics: The Science of Dosage form design. 3rd Edition, Churchill Livingstone. London, England: 340- 348.
[5] Lachman L, Liberman HA, Kanig JL. (1987). The theory and practice of Industrial Pharmacy, 3rd Edition, Philadelphia, PA: Lea and Febiger: 317-318.
[6] Higuchi T., Mechanism of sustained action medication: Theoritical analysis of rate of solid dispersed in solid matrices. J Pharm Sci, 1963:52(12):1145-1149.
[7] Koresmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm, 1983: 15:25-35.